FDA
-
-
-
-
-
-
-
Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR
-
-
-
-
-
-
-
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
-
-
-
-
-
-
-
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
-
-
-
-
-
-
-
Fate Therapeutics presents lupus trial data showing patient responses
-
-
-
-
-
-
-
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
-
330,010 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

